Booth
Visit Booth #400 to talk with cell-based assay experts
Presentation
Mechanism-driven Cell-based Assays to Screen & Characterize Bi- & Multi-specific Antibodies
Presenter: Jennifer Lin-Jones, Ph.D., Associate Director, Assay Dev., R&D Dept., Eurofins DiscoverX
Date: Tuesday May 12th | Time: 3:30pm | Session: Advances in Immunotherapy
Abstract: Advances in cancer immunotherapy have driven rapid growth in bi-specific and multi-specific antibodies that drive coordinated immune response modulation. As these modalities gain clinical traction, robust functional assays are essential to accelerate discovery and reduce risk. This presentation highlights cell-based cytotoxicity, receptor dimerization, and signaling assays, with case studies demonstrating mechanistic insight and target-specific validation for individual arms.
Posters
- Presenter: Alpana Prasad, Ph.D.
- Abstract: This study demonstrates an integrated approach for the comprehensive characterization of antibody–drug conjugates (ADCs) using complementary bioanalytical platforms. The objective was to evaluate target binding, internalization, and both payload- and Fc-mediated cytotoxic mechanisms to generate a holistic understanding of ADC MOA. An integrated workflow will be demonstrated to support discovery, optimization, and lot-release testing by linking molecular properties to functional outcomes, enhancing mechanistic understanding critical for ADC development.
Mechanism-driven Cell-based Assays to Screen & Characterize Bi-specific Antibodies
- Presenter: Gaurav Agrawal, Ph.D.
- Abstract: Bispecific antibodies (BsAbs) are engineered molecules designed to target two different epitopes or antigens. This poster highlights case studies (CD19, PD-1, CTLA4, VEGF-A) to demonstrate cell-based assays for monitoring key bispecific antibody mechanisms of actions. Here, we demonstrate how Eurofins DiscoverX cell-based assays are used evaluate tumor cell killing, rank-order candidates, and assess arm specificity, providing essential tools to accelerate next-generation BsAb discovery.
- Presenter: Jennifer Lin-Jones, Ph.D.
- Abstract: Checkpoint blockade antibodies, or checkpoint inhibitors, are established as effective cancer therapeutics. A contrasting class of therapeutics, agonistic checkpoint antibodies, has recently emerged for attenuating inflammation in autoimmune diseases. Here, we novel checkpoint assays in a co-culture format involving Fcγ receptor-expressing cells, directly measuring the stimulatory activity of agonistic antibodies. The assays for key checkpoint receptors such as CD40, CD137, PD-1, and BTLA are qualified for potency and stability studies.
Resources
- Delivering Solutions from Discovery to Market Brochure (Main Brochure)
- Accelerate Immuno-Oncology (Flyer)
- Measure Direct Cytotoxic Cell Death in Co-Culture (ADCC & ADCP) (Brochure)
- Immunotherapeutic eBook
- Antibody-Drug Conjugates (ADCs) (Case Study Brief)
- Comprehensive Cell-based Assays (Target/Product List)
- Cell-based Assays for Biologics Development Programs (Product List)
- GPCR Cell-based Assays (Target/Product List)
- Kinases (Target/Product List)